Laboratorios Rovi : Q4 2021 results and upgraded sales guidance for 2022e above expectations
>Laboratorios Rovi released another good set of results in Q4 2021 - Total revenues increased +57% y-o-y to € 186m (vs +56% in Q3 2021), 14% above our estimates and also 8% above the consensus, again showing a robust performance of the Moderna agreement on the mRNA COVID-19 vaccine (sales of toll manufacturing +232% y-o-y to € 85m, in line with expectations) and stronger- than-expected sales of heparins in the quarter: sales of Becat +31% y-o-y in Q4 2021 (vs flat in...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.